全文获取类型
收费全文 | 7002篇 |
免费 | 463篇 |
国内免费 | 167篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 29篇 |
妇产科学 | 7篇 |
基础医学 | 415篇 |
口腔科学 | 1747篇 |
临床医学 | 766篇 |
内科学 | 1227篇 |
皮肤病学 | 126篇 |
神经病学 | 765篇 |
特种医学 | 284篇 |
外科学 | 221篇 |
综合类 | 956篇 |
现状与发展 | 2篇 |
一般理论 | 4篇 |
预防医学 | 325篇 |
眼科学 | 48篇 |
药学 | 379篇 |
6篇 | |
中国医学 | 278篇 |
肿瘤学 | 37篇 |
出版年
2024年 | 21篇 |
2023年 | 129篇 |
2022年 | 266篇 |
2021年 | 350篇 |
2020年 | 286篇 |
2019年 | 276篇 |
2018年 | 261篇 |
2017年 | 263篇 |
2016年 | 242篇 |
2015年 | 216篇 |
2014年 | 457篇 |
2013年 | 465篇 |
2012年 | 357篇 |
2011年 | 344篇 |
2010年 | 299篇 |
2009年 | 253篇 |
2008年 | 297篇 |
2007年 | 291篇 |
2006年 | 253篇 |
2005年 | 211篇 |
2004年 | 173篇 |
2003年 | 170篇 |
2002年 | 128篇 |
2001年 | 164篇 |
2000年 | 99篇 |
1999年 | 69篇 |
1998年 | 102篇 |
1997年 | 78篇 |
1996年 | 77篇 |
1995年 | 77篇 |
1994年 | 66篇 |
1993年 | 69篇 |
1992年 | 98篇 |
1991年 | 73篇 |
1990年 | 66篇 |
1989年 | 53篇 |
1988年 | 54篇 |
1987年 | 52篇 |
1986年 | 56篇 |
1985年 | 50篇 |
1984年 | 46篇 |
1983年 | 47篇 |
1982年 | 45篇 |
1981年 | 32篇 |
1980年 | 35篇 |
1979年 | 19篇 |
1978年 | 15篇 |
1977年 | 22篇 |
1976年 | 17篇 |
1975年 | 24篇 |
排序方式: 共有7632条查询结果,搜索用时 171 毫秒
1.
2.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
3.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
4.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
5.
6.
7.
8.
目的 通过血清代谢组学技术,考察通阳化浊方与四妙勇安汤在治疗冠心病家兔中的作用机制。方法 40只雄性白兔,随机分为空白组、模型组、通阳化浊方组与四妙勇安汤组4组,每组10只。空白组正常饮食,模型组给予高脂饲料喂养至第8周,于第4周结束后,用球囊法手术损伤实验兔的右侧颈总动脉;在模型组基础上,两个实验组分别在术后,灌胃给予通阳化浊方和四妙勇安汤,连续4周,每日1次。给药结束后,模型组与实验组每组抽取3只家兔,采集全血后,用LC-MS技术进行血清代谢组学检测,运用PCA与OPLS-DA分析法来寻找差异性表达的代谢物和代谢途径。结果 相较于模型组,通阳化浊方与四妙勇安汤组分别存在45和27个差异化合物,通阳化浊方组涉及18条代谢通路,根据Impact值 > 0.05筛选出5条主要代谢通路,包括精氨酸和脯氨酸代谢、组氨酸代谢、牛磺酸和牛磺酸代谢、精氨酸生物合成和α-亚麻酸代谢;四妙勇安汤组涉及11条代谢通路,筛选出2条主要代谢通路分别为牛磺酸和牛磺酸代谢、组氨酸代谢。结论 通阳化浊方与四妙勇安汤在治疗冠心病模型家兔的过程中存在差异性代谢产物,干预相应的代谢通路可能会对药物在模型中的作用产生影响。 相似文献
9.
10.
Improving oral health: current considerations 总被引:1,自引:0,他引:1
S. Ciancio 《Journal of clinical periodontology》2003,30(S5):4-6